Humana Inc. (HUM) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $370.79 (-2.49%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 13, 2026 | George Hill | Deutsche Bank | $180.00 | -51.5% |
| Feb 12, 2026 | Sarah James | Raymond James | $201.00 | -45.8% |
| Feb 12, 2026 | Ben Hendrix | RBC Capital | $189.00 | -49.0% |
| Dec 18, 2025 | Erin Wright | Morgan Stanley | $262.00 | -29.3% |
| Dec 5, 2025 | David Windley | Jefferies | $313.00 | -15.6% |
| Nov 25, 2025 | Andrew Mok | Barclays | $234.00 | -36.9% |
| Oct 14, 2025 | Scott Fidel | Goldman Sachs | $235.00 | -36.6% |
| Oct 9, 2025 | Ann Hynes | Mizuho Securities | $345.00 | -7.0% |
| Sep 4, 2025 | Andrew Mok | Barclays | $315.00 | -15.0% |
| Sep 4, 2025 | Andrew Mok | Barclays | $325.00 | -12.3% |
| Jul 31, 2025 | Andrew Mok | Barclays | $275.00 | -25.8% |
| Jul 18, 2025 | Stephen Baxter | Wells Fargo | $348.00 | -6.1% |
| Jun 17, 2025 | David MacDonald | Truist Financial | $280.00 | -24.5% |
| Jun 12, 2025 | Andrew Mok | Barclays | $268.00 | -27.7% |
| Dec 4, 2024 | George Hill | Deutsche Bank | $248.00 | -33.1% |
| Oct 22, 2024 | George Hill | Deutsche Bank | $250.00 | -32.6% |
| Oct 10, 2024 | Andrew Mok | Barclays | $250.00 | -32.6% |
| Oct 8, 2024 | Ben Hendrix | RBC Capital | $265.00 | -28.5% |
| Oct 7, 2024 | David Windley | Jefferies | $253.00 | -31.8% |
| Oct 3, 2024 | Jessica Tassan | Piper Sandler | $274.00 | -26.1% |
Top Analysts Covering HUM
HUM vs Sector & Market
| Metric | HUM | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.97 | 2.24 | 2.40 |
| Analyst Count | 34 | 8 | 19 |
| Target Upside | -21.2% | +11475.1% | +17.1% |
| P/E Ratio | 39.66 | 3.87 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $159.06B | $161.64B | $167.37B | 17 |
| 2027-03-31 | $41.79B | $42.43B | $44.13B | 6 |
| 2027-06-30 | $42.25B | $42.90B | $44.61B | 6 |
| 2027-09-30 | $42.28B | $42.93B | $44.64B | 6 |
| 2027-12-31 | $42.47B | $43.12B | $44.85B | 6 |
| 2028-03-31 | $44.28B | $44.96B | $46.76B | 5 |
| 2028-06-30 | $44.88B | $45.57B | $47.40B | 5 |
| 2028-09-30 | $45.09B | $45.78B | $47.61B | 6 |
| 2028-12-31 | $45.28B | $45.97B | $47.81B | 8 |
| 2029-12-31 | $186.19B | $192.72B | $202.85B | 12 |
| 2030-12-31 | $197.50B | $204.44B | $215.18B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.96 | $8.82 | $9.63 | 16 |
| 2027-03-31 | $11.85 | $12.09 | $12.72 | 10 |
| 2027-06-30 | $6.24 | $6.36 | $6.69 | 7 |
| 2027-09-30 | $1.81 | $1.84 | $1.94 | 7 |
| 2027-12-31 | $-5.51 | $-5.24 | $-5.13 | 14 |
| 2028-03-31 | $14.76 | $15.05 | $15.83 | 11 |
| 2028-06-30 | $8.86 | $9.04 | $9.51 | 8 |
| 2028-09-30 | $3.58 | $3.65 | $3.84 | 8 |
| 2028-12-31 | $-4.25 | $-4.04 | $-3.96 | 15 |
| 2029-12-31 | $37.13 | $38.84 | $41.49 | 2 |
| 2030-12-31 | $39.79 | $41.63 | $44.47 | 5 |
Frequently Asked Questions
What is the analyst consensus for HUM?
The consensus among 34 analysts covering Humana Inc. (HUM) is Hold with an average price target of $235.00.
What is the highest price target for HUM?
The highest price target for HUM is $652.00, set by Nathan Rich at Goldman Sachs on 2022-12-13.
What is the lowest price target for HUM?
The lowest price target for HUM is $180.00, set by George Hill at Deutsche Bank on 2026-02-13.
How many analysts cover HUM?
34 analysts have issued ratings for Humana Inc. in the past 12 months.
Is HUM a buy or sell right now?
Based on 34 analyst ratings, HUM has a consensus rating of Hold (2.97/5) with a -21.2% upside to the consensus target of $235.00.
What are the earnings estimates for HUM?
Analysts estimate HUM will report EPS of $8.82 for the period ending 2026-12-31, with revenue estimated at $161.64B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.